DarioHealth Corp.
HealthcareNASDAQ:DRIO · NASDAQ Capital Market
-$0.14 today
Vol 0.00M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-61.4%
avg -176.4%
ROIC
-36.2%
avg -222.6%
ROA
-37.9%
avg -108.5%
Analysis
ROIC is currently the strongest return metric at -36.2% versus its period average of -222.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Erez Raphael | Chief Executive Officer & Director | $924,738.00 | — | 53 | $156,853.00 | 2.15% |
Steven C. Nelson | President & Chief Commercial Officer | $478,207.00 | — | 52 | $34,750.00 | 0.48% |
Chen Franco-Yehuda | Chief Financial Officer, Treasurer & Secretary | $374,226.00 | — | 42 | $30,000.00 | 0.41% |
Dov Oppenheim | Co-Founder & Production Chief | — | — | — | — | — |
Rob Halpern | SVP of Marketing | — | — | — | — | — |
Lara Dodo | Chief Operations Officer | — | — | — | — | — |
Claudia Levi | Content & Communications Manager | — | — | — | — | — |
Zoe Harrison | VP of Accounting & Corporate Development | — | — | — | — | — |
Mona Dean | Chief Compliance Officer | — | — | — | — | — |
Kat Parrella | Investor Relations Manager | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$21,200.00
Sells
0
$0.00
Net Sentiment
+$21,200.00
Net buying
Most Active
Nelson Steven Charles
1 transactions
Analysis
Insiders reported 1 buys worth $21,200.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $21,200.00. Nelson Steven Charles was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +27.6% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +27.6% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
InnovAge Holding Corp.
NASDAQ:INNV
$1.24B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
Absci Corporation
NASDAQ:ABSI
$1.06B
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
$684.26M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$530.52M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$406.89M
Orthofix Medical Inc.
NASDAQ:OFIX
$376.33M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Who manages DRIO?
DarioHealth Corp. (DRIO) lists 10 active executives. The top listed executive is Erez Raphael, Chief Executive Officer & Director.
Are DRIO insiders buying or selling?
Recent insider activity shows net buying of $7.16M.
Explore More
Continue the stock analysis
Jump to another research area for this company.